Phase Ib/II Clinical Study of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Latest Information Update: 19 Sep 2023
At a glance
- Drugs GNC 035 (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.
- 18 Jul 2023 New trial record